SAGE News and Press, Sage Therapeutics Inc.

2024-06-20 13:15:04 ET Scotiabank analyst issues UNDERPERFORM recommendation for SAGE on June 20, 2024 10:00AM ET. The previous analyst recommendation was Underperform. SAGE was trading at $10.525 at issue of the analyst recommendation. The overall analyst consensus : HO...

2024-06-20 13:15:04 ET Wedbush analyst issues SECTOR PERFORM recommendation for SAGE on June 20, 2024 10:00AM ET. The previous analyst recommendation was Sector Perform. SAGE was trading at $10.525 at issue of the analyst recommendation. The overall analyst consensus : H...

2024-06-11 08:23:47 ET More on Sage Therapeutics Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data Sage Therapeutics, Inc.(SAGE) Q1 2024 Earnings Call Transcript Sage Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation ...

The SURVEYOR Study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery ( HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment ...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 2:00 p...

2024-06-02 19:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-30 12:24:45 ET Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patient...

2024-05-29 09:25:54 ET Sage Therapeutics ( NASDAQ: SAGE ) initiated at Sell/High Risk by Citi as it believes the company will face outsized commercial, clinical, and regulatory risks over the next 12 months.... Read the full article on Seeking Alpha For further details s...

2024-05-28 19:15:01 ET Citigroup analyst issues SELL recommendation for SAGE on May 28, 2024 05:36PM ET. SAGE was trading at $11.93 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 3 - Buy, 4 - Hold recom...

2024-05-28 18:00:05 ET Joel Beatty from Robert W. Baird issued a price target of $15.00 for SAGE on 2024-05-28 16:15:00. The adjusted price target was set to $15.00. At the time of the announcement, SAGE was trading at $11.93. The overall price target consensus is at $49...